Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Relief Therapeutics Holding AG    RLF   CH0100191136

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Relief Therapeutics : Selects CRO and CDMO for RLF-100TM in Europe

11/18/2020 | 01:09am EST
  • European clinical assessment of RLF-100™ for the treatment of COVID-19 induced lung injury planned to begin in Q1 2021

Geneva, Switzerland, November 18, 2020 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ('Relief' or the 'Company'), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Syneos Health® (Nasdaq:SYNH), a leading global clinical research organization (CRO), to run the European clinical trial in severe COVID-19 induced lung injury, as well as future trials in other indications to be conducted in Europe. Relief has also selected AMRI, a global contract development and manufacturing organization (CDMO), who will provide aseptic fill/finish manufacturing of RLF-100TM at their Glasgow, UK, facility. European clinical assessment of RLF-100TM is slated to begin in Q1 2021.

Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, commented: 'We are pleased to bring on board highly experienced service partners that are critical to successfully advancing our clinical development activities in Europe. As a global therapeutically aligned organization, Syneos Health® brings forward deep respiratory therapeutic expertise and the ability to activate clinical trials across multiple countries. AMRI's Glasgow team is a renowned global provider of contract manufacturing services and will support our sterile fill/finish drug product manufacturing needs. We believe these collaborations position Relief to develop RLF-100™ as quickly as possible in Europe.'

###

ABOUT RELIEF

Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100™ (aviptadil), synthetic vasoactive intestinal peptide (VIP), is being investigated, in cooperation with NeuroRx Inc., in two placebo-controlled U.S. Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. RLF-100™ is believed to be the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100™ under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100™.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.

Disclaimer

Relief Therapeutics Holding AG published this content on 18 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 November 2020 06:08:04 UTC


© Publicnow 2020
All news about RELIEF THERAPEUTICS HOLDING AG
01/11RELIEF, NEURORX AND QUANTUM LEAP ANN : aviptadil) in the I-SPY COVID-19 Trial
PU
01/11NeuroRx, RELIEF THERAPEUTICS Signs Contract To Include COVID-19 Drug In I-SPY..
MT
01/11NEURORX, RELIEF, AND QUANTUM LEAP AN : aviptadil) in the I-SPY COVID-19 Trial
PR
01/11EQS-NEWS : Relief, NeuroRx and Quantum Leap -2-
DJ
01/11EQS-NEWS : Relief, NeuroRx and Quantum Leap announce the inclusion of ZYESAMI(TM..
DJ
2020RELIEF THERAPEUTICS : stock plunges after FDA rejects COVID-19 emergency approva..
RE
2020Relief Therapeutics, NeuroRx Finish Enrollment for COVID-19 Treatment Trial
MT
2020RELIEF THERAPEUTICS : and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial ..
PU
2020NEURORX : and Relief Conclude Enrollment in their Phase 2b/3 Trial of RLF-100&tr..
PR
2020EQS-NEWS : Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of R..
DJ
More news
Financials
Sales 2019 - - -
Net income 2019 -7,46 M -8,37 M -8,37 M
Net Debt 2019 1,61 M 1,81 M 1,81 M
P/E ratio 2019 -0,28x
Yield 2019 -
Capitalization 1 000 M 1 124 M 1 121 M
EV / Sales 2018 20,5x
EV / Sales 2019 -
Nbr of Employees 10
Free-Float 51,6%
Chart RELIEF THERAPEUTICS HOLDING AG
Duration : Period :
Relief Therapeutics Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RELIEF THERAPEUTICS HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Managers and Directors
NameTitle
Raghuram Selvaraju Chairman
Jack M. Weinstein Chief Financial Officer & Treasurer
Gilles Della Corte Chief Medical Officer
Peter Egon de Svastich Director
Jonathan C. Javitt Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
RELIEF THERAPEUTICS HOLDING AG14.50%1 124
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-8.36%40 715
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601